August 12, 2015
David Chen, Hydrogen’s life sciences consultant and pharmacovigilance market expert, joined an industry panel at Pharmacovigilance Europe 2015 to discuss the ‘Implication of strengthened transparency, accountability, communication and patient involvement’.
Hosted at the charismatic Kensington Close Hotel, David was also joined by industry experts and regulators to debate on how pharmaceutical companies can better communicate about adverse drug reactions to all stakeholders, especially the general public.
Speaking about the conference, David commented, “The internet has created an almost infinite pool of data. The public’s demand for transparency stems from wanting the industry to be more open and communicative about the profile of a drug, so that they can better understand the risks involved to make more informed decisions on which treatment is most suitable.”
“Being invited to talk at this conference allows us to mediate between the industry and the general public, to present an objective view, while communicating our learning on what the two parties want based on our good relations.”
To keep in theme with Pharmacovigilance Europe’s conference, we've presented our viewpoint on how the pharmacovigilance legislation will impact the market once it comes into affect in 2016.